SAGE Therapeutics (SAGE) Reports In-Line Q2 EPS

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.13), in-line with the analyst estimate of ($2.13). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Benchmark Reiterates Hold Rating on Old Dominion Freight Line (ODFL) as 'Quality Largely Priced in'
• GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says